IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
36.01
+0.08 (0.22%)
At close: Jul 17, 2026, 4:00 PM EDT
36.50
+0.49 (1.36%)
After-hours: Jul 17, 2026, 4:15 PM EDT
IDEAYA Biosciences Revenue
IDEAYA Biosciences had revenue of $6.56M in the quarter ending March 31, 2026. In the year 2025, IDEAYA Biosciences had annual revenue of $218.71M with 3,024.43% growth.
Revenue (ttm)
$218.71M
Revenue Growth
+3,024.43%
P/S Ratio
15.20
Revenue / Employee
$1,553,586
Employees
145
Market Cap
3.42B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 218.71M | 211.71M | 3,024.43% |
| Dec 31, 2024 | 7.00M | -16.39M | -70.07% |
| Dec 31, 2023 | 23.39M | -27.55M | -54.08% |
| Dec 31, 2022 | 50.93M | 22.99M | 82.28% |
| Dec 31, 2021 | 27.94M | 8.40M | 43.01% |
| Dec 31, 2020 | 19.54M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Telix Pharmaceuticals | 803.79M |
| Ultragenyx Pharmaceutical | 670.00M |
| Arcutis Biotherapeutics | 415.62M |
| Arcus Biosciences | 236.00M |
| NewAmsterdam Pharma Company | 22.57M |
| Alumis | 8.40M |
IDYA News
- 17 hours ago - IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs - PRNewsWire
- 10 days ago - Ideaya Biosciences price target lowered to $63 from $65 at Truist - TheFly
- 10 days ago - Ideaya Biosciences price target lowered to $48 from $53 at RBC Capital - TheFly
- 21 days ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 4 weeks ago - Ideaya Biosciences elects CEO Yujiro Hata as chairman - TheFly
- 4 weeks ago - IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors - PRNewsWire
- 4 weeks ago - Ideaya Biosciences enrolls first patient in IDE892 trial - TheFly
- 4 weeks ago - IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers - PRNewsWire